Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
AstraZeneca will acquire Neogene for up to $320 million
by Gina Vitale
December 1, 2022
| A version of this story appeared in
Volume 100, Issue 43
AstraZeneca has agreed to acquire the T-cell receptor (TCR) therapy company Neogene for $200 million on closing and up to $120 million in other payments. Many T-cell therapies involve getting a person’s T cells to recognize a protein on the surface of cancer cells; TCR therapies are able to recognize intracellular targets, the companies say, which could broaden their available targets. The firms say they aim to deliver cell therapies to people with solid tumors.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter